Cardiac sarcoidosis: Diagnosis and management

Postgraduate Medical Journal

Volumn 91, Issue 1077, 2015, Pages 384-394

  Dubrey, Simon W ^a   Sharma, R ^b   Underwood, R ^c   Mittal, T ^c  

^a HILLINGDON HOSPITAL   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE; FLUORODEOXYGLUCOSE; GALLIUM; HLA A2 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; CALCIUM; VITAMIN D;

CARDIOVASCULAR MAGNETIC RESONANCE; CONGESTIVE HEART FAILURE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; GENETICS; HEART ARRHYTHMIA; HEART BLOCK; HEART ELECTROPHYSIOLOGY; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LYMPHADENOPATHY; MYOCARDIAL PERFUSION IMAGING; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; REVIEW; SARCOIDOSIS; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THORAX RADIOGRAPHY; BLOOD; CARDIOMYOPATHIES; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENETIC PREDISPOSITION; GENETIC SCREENING; INCIDENTAL FINDING; JAPAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PROGNOSIS; TRENDS;

CALCIUM; CARDIOMYOPATHIES; ELECTROCARDIOGRAPHY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; INCIDENTAL FINDINGS; JAPAN; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SARCOIDOSIS; TOMOGRAPHY, X-RAY COMPUTED; VITAMIN D;

EID: 84937510818     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2014-133219     Document Type: Review

References (139)

1. Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: a Delphi study. Chest 2012;141:154–62.
2. Birnie DH, Sauer WH, Bogun F, et al. HRS Expert Consensus Statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11:1304–22.
3. Baughman RP, Tierstein AS, Judson MA, et al. Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Resp Crit Care Med 2001;164(10 pt 1):1885–9.
4. Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest 1993;103:253–8.
5. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978;58:1204–11.
6. Iwai K, Sekiguchi M, Hosoda Y, et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis 1994;11:26–31.
7. Matsui Y, Iwai K, Tachibana Y, et al. Clinicopathological study on fatal myocardial sarcoidosis. Ann NY Acad Sci 1976;278:455–69.
8. Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. Eur Resp J 2008;31:372–9.
9. Roberts WC, McAllister Jr HA, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med 1977;63:86–108.
10. Nunes H, Freynet O, Naggara N, et al. Cardiac sarcoidosis. Semin Respir Crit Care Med 2010;31:428–41.
11. Sekhri V, Sanal S, DeLorenzo LJ, et al. Cardiac sarcoidosis: a comprehensive review. Arch Med Sci 2011;7:546–54.
12. Kim DS. Sarcoidosis in Korea: report of the Second National Survey. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:176–80.
13. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisolone. Am J Cardiol 2001;88:1006–10.
14. Sekiguchi M, Numao Y, Imai M, et al. Clinical and histopathological profile of sarcoidosis of the heart and acute idiopathic myocarditis. Concepts through a study employing endomyocardial biopsy. Jpn Circ J 1980;44:249–63.
15. Deng JC, Baughman RP, Lynch JP. Cardiac involvement in sarcoidosis. Sem Respir Crit Care Med 2002;23:513–27.
16. Huang CT, Heurich AE, Sutton AL, et al. Mortality in sarcoidosis. A changing pattern of the cause of death. Eur J Resp Dis 1981;62:231–8.
17. Iwai K, Tachibana T, Takemura T, et al. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn 1993;43:372–6.
18. Darlington P, Gabrielsen A, Sorensson P, et al. Cardiac involvement in Caucasian patients with pulmonary sarcoidosis. Resp Res 2014;15:15–20.
19. Hills SE, Parkes SA, Baker SBdC. Epidemiology of sarcoidosis on the Isle of Man-2: evidence for space-time clustering. Thorax 1987;42:427–30.
20. Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis. A case-control etiological study of sarcoidosis (ACCESS). Am J Resp Crit Care Med 2001;164:2085–91.
21. Sato H, Woodhead FA, Ahmad T, et al. Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. Hum Molec Genetics 2010;19:4100–11.
22. Darlington P, Gabrielsen A, Sorensson P, et al. HLA-alleles associated with increased risk for extra-pulmonary involvement in sarcoidosis. Tissue Antigens 2014;83:267–72.
23. Hofmann S, Fischer A, Till A, et al. A genome-wide association study reveals evidence of association with sarcoidosis. Eur Resp J 2011;38:1127–35.
24. Rossman MD, Thompson B, Frederick M, et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in Blacks and Whites. Am J Hum Genet 2003;73:720–35.
25. Rossman MD, Kreider ME. Lesson learned from ACCESS (a case controlled etiologic study of sarcoidosis). Proc Am Thorac Soc 2007;4:453–6.
26. Naruse TK, Matsuzawa Y, Ota M, et al. HLA DQB*0601 is primarily associated with the susceptibility to cardiac sarcoidosis. Tissue Antigens 2000;56:52–7.
27. Takashige N, Naruse TK, Matsumori A, et al. Genetic polymorphisms at the tumour necrosis factor loci (TFNA and TFNB) in cardiac sarcoidosis. Tissue Antigens 1999;54:191–3.
28. Nakai K, Syoh T, Hiramori K. [Angiotensin-I converting enzyme]. Nihon Rinsho 1995;53:1232–6.
29. Sekiguchi M, Yazaki Y, Isobe M, et al. Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Cardiovasac Drugs Therapy 1996;10:495–510.
30. Zipse MM, Sauer WH. Cardiac sarcoidosis. Curr Cardiol Rep 2014;16:514–24.
31. Valeyre D, Prasse A, Nunes H, et al. Sarcoidosis. Lancet 2014;383:1155–67.
32. Newman LS, Rose CS, Bresnitz EA. A case control etiological study of sarcoidosis: environmental and occupational risk factors. Am J Resp Crit Care Med 2004;170:1324–30.
33. Newman KL, Newman LS. Occupational causes of sarcoidosis. Curr Opin Allergy Immunol 2012;12:145–50.
34. McGrath DS, Daniil Z, Foley P, et al. Epidemiology of familial sarcoidosis in the UK. Thorax 2000;55:751–4.
35. Sverrild A, Backer V, Kyvik KO, et al. Heredity in sarcoidosis: a registry based twin study. Thorax 2008;63:894–6.
36. Viles-Gonzales JF, Pastori L, Fischer A, et al. Supraventricular arrhythmias in patients with cardiac sarcoidosis: prevalence, predictors and clinical implications. Chest 2013;143:1085–90.
37. Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis 2010;52:336–46.
38. Nery PB, Leung E, Birnie DH. Arrhythmias in cardiac sarcoidosis: diagnosis and treatment. Curr Opin Cardiol 2012;27:181–9.
39. Corte TJ, Wells AU, Nicholson AG, et al. Pulmonary hypertension in sarcoidosis: a review. Respirology 2011;16:69–77.
40. Lewin RF, Mor R, Spitzer S, et al. Echocardiographic evaluation of patients with systemic sarcoidosis. Am Heart J 1985;110:116–22.
41. Navaneethan SD, Venkatesh S, Shrivastava R, et al. Recurrent pleural and pericardial effusions due to sarcoidosis. PLoS Med 2005;2:e63.
42. Pesola G, Teirstein AS, Goldman M. Sarcoidosis presenting with pericardial effusion. Sarcoidosis 1987;4:42–4.
43. Studdy PR, Bird R, Neville E, et al. Biochemical findings in sarcoidosis. J Clin Pathol 1980;33:528–33.
44. Sharma OP. Hypercalcaemia in granulomatous disorders: a clinical review. Curr Opin Pulmon Med 2000;6:442–7.
45. Iannuzzi MC, Rybicki BA, Tierstein AS. Sarcoidosis. N Engl J Med 2007;357:2153–65.
46. Adamson P, Melton I, O’Donnell J, et al. Cardiac sarcoidosis: the Christchurch experience. Int Med J 2014;44:70–6.
47. Ainslie GM, Benatar SR. Serum angiotensin converting enzyme in sarcoidosis: sensitivity and specificity in diagnosis: correlations with disease activity, duration, extrathoracic involvement, radiographic type and therapy. Q J Med 1985;55:253–70.
48. Saussine A, Tazi A, Feuillet S, et al. Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels. PLoS ONE 2012;7:e43588.
49. Doughan AR, Williams BR. Cardiac sarcoidosis. Heart 2006;92:282–8.
50. Divakara Menom SM, Chemello D, Morillo CA. Sarcoidosis: yet another masquerader the cardiologist/electrophysiologist has to fight with. Pacing Electrophysiol J 2010;10:479–85.
51. Schuller JL, Olson MD, Zipse MM, et al. Electrocardiographic characteristics in patients with pulmonary sarcoidosis indicating cardiac involvement. J Cardiovasc Electrophysiol 2011;22:1243–8.
52. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J 2009;157:9–21.
53. Suzuki T, Tsugiyasu K, Kubata S, et al. Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis. Chest 1994;106:1021–4.
54. Hirago K, Yuwai K, Hiroe M. Guideline for diagnosis of cardiac sarcoidosis: study report on diffuse pulmonary disease from the Japanese Ministry of Health and Welfare. Tokyo, Japan. Japanese Ministry of Health and Welfare, 1993:23–4.
55. Valantine H, Mckenna WJ, Nihoyannopoulos P, et al. Sarcoidosis a pattern of clinical and morphological presentation. Br Heart J 1987;57:256–63.
56. Burstow DJ, Tajik J, Bailey KR, et al. Two-dimensional echocardiographic findings in systemic sarcoidosis. Am J Cardiol 1989;63:478–82.
57. Yamano T, Nakatani S. Cardiac sarcoidosis: what can we know from echocardiography. J Echocardiogr 2007;5:1–10.
58. Nureki S-I, Miyazaki E, Nishio S, et al. Interventricular septal thickening as an early manifestation of cardiac sarcoidosis. Int Heart J 2014;55:181–3.
59. Fahy GJ, Marwick T, McCreery CJ, et al. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest 1996;109:62–6.
60. Gibbons WJ, Levy RD, Nava S, et al. Subclinical cardiac dysfunction in sarcoidosis. Chest 1991;100:44–50.
61. Hourigan LA, Burstow DJ, Pohlner P, et al. Transesophageal echocardigraphic abnormalities in a case of cardiac sarcoidosis. J Am Soc Echocardiog 2001;14:399–402.
62. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Cardiac involvement in patients with pulmonary sarcoidosis assessed at two University Medical Centers in the Netherlands. Chest 2005;128:30–5.
63. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969–77.
64. Diagnostic standards and guidelines for sarcoidosis. Jp J Sarcoidosis Granulomatous Disoders 2007;27:89–102.
65. Judson MA, Costabel U, Drent M, et al. The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffuse Dis 2014;31:19–27.
66. Parsai C, O’Hanlon R, Prasad SK, et al. Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies. J Cardiovasc Magn Reson 2012;14:54.
67. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005;45:1683–90.
68. Patel AR, Klein MR, Chandra S, et al. Myocardial damage in patients with sarcoidosis and reserved left ventricular systolic function: an observational study. Eur J Heart Fail 2011;13:1231–7.
69. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2013;6:501–11.
70. Muth G, Daniel WG, Achenbach S. Late enhancement on cardiac computed tomography in a patient with cardiac sarcoidosis. J Cardiovasc Comput Tomography 2008;2:272–3.
71. Jamar F, Buscombe J, Chiti A. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med 2013;54:647–58.
72. Kita T, Watanabe S, Yano F, et al. Clinical significance of the serum IL-2R level and Ga-67 scan findings in making a differential diagnosis between sarcoidosis and non-Hodgkin’s lymphoma. Ann Nucl Med 2007;21:499–503.
73. Statement on sarcoidosis. Joint statement of the ATS, ERS and WASOG. Am J Respir Crit Care Med 1999;160:736–55.
74. Okayama K, Kurata C, Tawarahara K, et al. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest 1995;107:330–4.
75. Futamatsu H, Suzuki J, Adachi S, et al. Utility of gallium-67 scintigraphy for evaluation of cardiac sarcoidosis with ventricular tachycardia. Int J Cardiovasc Imaging 2006;22:443–8.
76. Banba K, Kusano KF, Nakamura K, et al. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm 2007;4:1292–9.
77. Eguchi M, Tsuchihashi K, Hotta D, et al. Technetium-99m sestamibi/tetrofosmin myocardial perfusion scanning in cardiac and noncardiac sarcoidosis. Cardiology 2000;94:193–9.
78. Nakazawa A, Ikeda K, Ito Y, et al. Usefulness of dual 67Ga and 99mTc-sestamibi single-photon-emission CT scanning in the diagnosis of cardiac sarcoidosis. Chest 2004;126:1372–6.
79. Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329–36.
80. Teirstein AS, Machac J, Almeida E, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007;132:1949–53.
81. Fukuchi K, Ohta H, Matsumura K, et al. Benign variations and incidental abnormalities of myocardial FDG uptake in the fasting state as encountered during routine oncology positron emission tomography studies. Br J Radiol 2007;80:3–11.
82. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012;53:241–8.
83. Ahmadian A, Brogan A, Berman J, et al. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol 2014;21:925–39.
84. Mc Ardle BA, Birnie DH, Klein R, et al. Is there an association between clinical presentation and the location and extent of myocardial involvement of cardiac sarcoidosis as assessed by 18F-fluorodoexyglucose positron emission tomography? Circ Cardiovasc Imaging 2014;6:617–26.
85. McArdle BA, Leung E, Ohira H, et al. The role of F(18)-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis. J Nucl Cardiol 2013;20:297–306.
86. Osborne MT, Hulten EA, Singh A, et al. Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 2014;21:166–74.
87. Skali H, Schulman AR, Dorbala S. 18F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep 2013;15:352–63.
88. Evanchan JP, Crouser ED, Kalbfleisch SJ. Cardiac sarcoidosis: recent advances in diagnosis and treatment and an argument for the need for a systemic multi-disciplinary approach to management. J Innovations Card Rhythm Manage 2013;4:1160–74.
89. Morooka M, Moroi M, Uno K, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res 2014;4:1–11.
90. Ohira H, Tsujino I, Ishimaru S, et al. Myocardial imaging with 18F-fluoro-2- deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008;35:933–41.
91. Tahara N, Tahara A, Nitta Y, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 2010;3:1219–28.
92. Isiguzo M, Brunken R, Tchou P, et al. Metabolism-perfusion imaging to predict disease activity in cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011;28:50–5.
93. Uemura A, Morimoto S-I, Hiramitsu S, et al. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J 1999;138:299–302.
94. Kato Y, Morimoto S, Uemura A, et al. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis 2003;20:133–7.
95. Yodogawa K, Seino Y, Shiomura R, et al. Recovery of atrioventricular block following steroid therapy in patients with cardiac sarcoidosis. J Cardiol 2013;62:320–5.
96. Chiu CZ, Nakatani S, Zhang G, et al. Prevention of left ventricular re-modelling by long term corticosteroid therapy in patents with cardiac sarcoidosis. Am J Cardiol 2005;95:143–6.
97. Sadek MM, Yung D, Birnie DH, et al. Corticosteroid therapy for cardiac sarcoidosis: a systemic review. Can J Cardiol 2013;29:1034–41.
98. Tanada Y, Sato Y, Sawa T, et al. Serial measurement of high-sensitivity cardiac troponin I and N-terminal proB-type natriuretic peptide in a patient presenting with cardiac sarcoidosis. Intern Med 2012;51:3379–81.
99. Baba Y, Kubo T, Kitaoka H, et al. Usefulness of high-sensitive cardiac troponin T for evaluating the activity of cardiac sarcoidosis. Int Heart J 2012;53:287–92.
100. Beegle SH, Barba K, Gobunsay R, et al. Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des Dev Therap 2013;7:325–38.
101. Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol 2009;20:578–83.
102. Lakdawala NK, Givertz MM. Dilated cardiomyopathy with conduction disease and arrhythmia. Circulation 2010;122:527–34.
103. Yazaki Y. The diagnostic dilemma of isolated cardiac sarcoidosis. Intern Med 2013;52:1–2.
104. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:149–73.
105. Paramothayan S, Lasserson TJ, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev 2006;(3): CD003536.
106. Chapelon-Abric C, De Zuttere D, Duhaut P, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine 2004;83:315–34.
107. Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50 year experience at the John Hopkins Hospital. Medicine (Baltimore) 1999;78:65–111.
108. Johns CP, Scott PP, Schonfeld SA. Sarcoidosis. Ann Rev Med 1989;40:353–7.
109. Fusano KF. Effect of corticosteroid on arrhythmic events in patients with cardiac sarcoidosis. J Cardiol 2013;62:326–7.
110. Baughman RP, Nunes H. Therapy for sarcoidosis: evidence based recommendations. Exp Rev Clin Immunol 2012;8:95–103.
111. Demeter SL. Myocardial sarcoidosis unresponsive to steroids: treatment with cyclophosphamide. Chest 1988;94:202–3.
112. Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med 2008;29:533–48.
113. Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous disorders recommendations for the use of methotrexate in sarcoidosis: integrating systemic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med 2013;19:545–61.
114. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000;17:60–6.
115. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795–802.
116. Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Resp Med 2010;104:717–23.
117. Londner C, Zendah I, Freynet O, et al. Treatment of sarcoidosis. Rev Med Interne 2011;32:109–13.
118. Jefic D, Joel B, Good E, et al. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm 2009;6:189–95.
119. Uusimaa P, Ylitalo K, Anttonen O, et al. Ventricular tachyarrhythmia as a primary presentation of sarcoidosis. Europace 2008;10:760–6.
120. Winters SL, Cohen M, Greenberg S, et al. Sustained ventricular tachycardia associated with sarcoidosis; assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable anti-tachycardia device. J Am Coll Cardiol 1991;18:937–43.
121. Syed J, Myers R. Sarcoid heart disease. Can J Cardiol 2004;20:89–93.
122. Naik AM, Patel SB. Ventricular tachycardia storm in cardiac sarcoidosis: a 76-day-ICU-nightmare. Ind Pacing Electrophsiol J 2012;12:278–83.
123. Dubrey SW, Bell A, Mittal TK. Sarcoid heart disease. Postgrad Med J 2007;83:618–23.
124. Fleming HA. Cardiac sarcoidosis. Semin Respir Med 1986;8:65–71.
125. Heck PM, Roberts PR. The role of implantable cardiac defibrillators in cardiac sarcoidosis: savior or sinner? Europace 2013;15:309–10.
126. Kron J, Sauer W, Schuller J, et al. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace 2013;15:347–54.
127. Schuller JL, Zipse M, Crawford T, et al. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol 2012;23:925–9.
128. Betensky BP, Tschabrunn CM, Zado ES, et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 2012;6:884–91.
129. Valantine HA, Tazelaar HD, Macoviak J, et al. Cardiac sarcoidosis: response to steroids and transplantation. J Heart Transplant 1987;6:244–50.
130. Zaidi AR, Zaidi A, Vaitkus PT. Outcome of heart transplantation in patients with sarcoid cardiomyopathy. J Heart Lung Transplant 2007;26:714–7.
131. Perkel D, Czer LS, Morrissey RP, et al. Heart transplantation for end-stage heart failure due to cardiac sarcoidosis. Transplant Proc 2013;45:2384–6.
132. Padilla ML, Schillero GJ, Teirstein AS. Donor acquired sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:18–24.
133. Yager JE, Hernandez AF, Steenbegen C, et al. Recurrence of cardiac sarcoidosis in a heart transplant recipient. J Heart Lung Transplant 2005;24:1988–90.
134. Oni AA, Hershberger RE, Norman DJ, et al. Recurrence of sarcoidosis in a cardiac allograft: control with augmented corticosteroids. J Heart lung Transplant 1992;11:367–9.
135. Burke WM, Keogh A, Maloney PJ, et al. Transmission of sarcoidosis via cardiac transplantation. Lancet 1990;336:1579.
136. Spagnolo P, du Bois RM. Genetics of sarcoidosis. Clin Dermatol 2007;25:242–9.
137. Spagnolo P, Grunewald J. Recent advances in the genetics of sarcoidosis. J Med Genet 2013;50:290–7.
138. Morgenthau AS, Iannuzzi MC. Recent advances in sarcoidosis. Chest 2011;139:174–82.
139. Lynch JP, Hwang J, Bradfield J, et al. Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment. Semin Resp Crit Care Med 2014;35:372–90.